微創醫療(00853.HK)完成配售6595.8萬股新股
格隆匯 7 月 2日丨微創醫療(00853.HK)公告,董事會欣然宣佈配售協議項下所有先決條件已獲達成,且配售事項已於2020年7月2日完成。
合共6595.8萬股新股份(約佔公司截至公告日期經配售股份擴大後已發行股3.66%)已2由配售代理以每股23.50港元價格成功配售予不少於六名承配人。
來自配售事項的所得款項淨額(經扣除所有相關成、佣金及開支後)約為15.41億港元。公司擬將該等所得款項淨額用於償還集團銀行貸款、為將來潛在業務發展及投資(如有該等機會)提供資金以及用作集團一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.